Pictured: ESK1 Monoclonal Antibody
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, March 13, 2013

Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.

Pictured: Major Trends in Modern Cancer Research Seminar
Video
By Julie Grisham, MS, Science Writer/Editor  |  Friday, March 1, 2013

At the seventh annual seminar for high school students and teachers, investigators discuss how cutting-edge biomedical research may ultimately contribute to better treatments for cancer patients.

Pictured: Charles Sawyers
Honor
By Media Staff  |  Wednesday, February 20, 2013

Charles Sawyers, Chair of Memorial Sloan Kettering’s Human Oncology and Pathogenesis Program, is a recipient of the inaugural $3 million prize for groundbreaking achievements in scientific research.

Pictured: Charles Sawyers' Laboratory
In the Clinic
By Media Staff  |  Monday, January 7, 2013

The American Society of Clinical Oncology’s notable research advances include the approval of a new drug for men with advanced prostate cancer that was developed and studied by Memorial Sloan Kettering researchers.

Pictured: PET Scan
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, November 15, 2012

Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Pictured: Ping Chi
Q&A
By Julie Grisham, MS, Science Writer/Editor  |  Friday, November 2, 2012

Dr. Chi, a physician-scientist and member of the Human Oncology and Pathogenesis Program, studies genetic and epigenetic changes that cause cancer.

In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, September 17, 2012

When new cancer drugs are shown to be largely ineffective, exceptional cases of good outcome may pave the way for new treatments that could benefit a smaller group of patients.

Pictured: Charles Sawyers & Howard Scher
Announcement
By Memorial Sloan Kettering  |  Friday, August 31, 2012

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Monday, May 21, 2012

Results of an international study indicate that the investigational drug tivozanib is more effective and better tolerated than a currently approved therapy in delaying cancer growth.

Pictured: Robert Motzer
In the Clinic
By Esther Napolitano, BS, Science Writer/Editor  |  Tuesday, February 7, 2012

The recent FDA approval of axitinib provides a viable treatment option for patients who progress on or cannot tolerate the side effects of other approved drugs for the disease.

Pictured: Memorial Sloan Kettering logo
In the News
By Julie Grisham, MS, Science Writer/Editor  |  Monday, February 6, 2012

Two of the year’s top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.

Pictured: Charles Sawyers & Howard Scher
In the News
By Media Staff  |  Friday, February 3, 2012

The success of an experimental prostate cancer treatment is an example of how academic research centers are playing a larger role in drug development, the Wall Street Journal reports.

Pictured: Nancy Lee
In the Clinic
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, December 19, 2011

People with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy, according to an international study led by Memorial Sloan Kettering radiation oncologist Nancy Y. Lee.

Pictured: David Solit
In the Lab
By Media Staff  |  Wednesday, November 23, 2011

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.